Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Constantinos T. Sofocleous is active.

Publication


Featured researches published by Constantinos T. Sofocleous.


Journal of The National Comprehensive Cancer Network | 2018

Clinical practice guidelines in oncology

Al B. Benson; J. Pablo Arnoletti; Tanios Bekaii-Saab; Emily Chan; Yi Jen Chen; Michael A. Choti; Harry S. Cooper; Raza A. Dilawari; Paul F. Engstrom; Peter C. Enzinger; James W. Fleshman; Charles S. Fuchs; Jean L. Grem; James A. Knol; Lucille Leong; Edward Lin; Kilian Salerno May; Mary F. Mulcahy; Kate Murphy; Eric Rohren; David P. Ryan; Leonard Saltz; Sunil Sharma; David Shibata; John M. Skibber; William Small; Constantinos T. Sofocleous; Alan P. Venook; Christopher G. Willett

Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions in the breast ducts. The goal for management of DCIS is to prevent the development of invasive breast cancer. This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.


Radiology | 2014

Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update

Muneeb Ahmed; Luigi Solbiati; Christopher L. Brace; David J. Breen; Matthew R. Callstrom; J. William Charboneau; Min-Hua Chen; Byung Ihn Choi; Thierry de Baere; Gerald D. Dodd; Damian E. Dupuy; Debra A. Gervais; David Gianfelice; Alice R. Gillams; Fred T. Lee; Edward Leen; Riccardo Lencioni; Peter Littrup; Tito Livraghi; David Lu; John P. McGahan; Maria Franca Meloni; Boris Nikolic; Philippe L. Pereira; Ping Liang; Hyunchul Rhim; Steven C. Rose; Riad Salem; Constantinos T. Sofocleous; Stephen B. Solomon

Image-guided tumor ablation has become a well-established hallmark of local cancer therapy. The breadth of options available in this growing field increases the need for standardization of terminology and reporting criteria to facilitate effective communication of ideas and appropriate comparison among treatments that use different technologies, such as chemical (eg, ethanol or acetic acid) ablation, thermal therapies (eg, radiofrequency, laser, microwave, focused ultrasound, and cryoablation) and newer ablative modalities such as irreversible electroporation. This updated consensus document provides a framework that will facilitate the clearest communication among investigators regarding ablative technologies. An appropriate vehicle is proposed for reporting the various aspects of image-guided ablation therapy including classification of therapies, procedure terms, descriptors of imaging guidance, and terminology for imaging and pathologic findings. Methods are addressed for standardizing reporting of technique, follow-up, complications, and clinical results. As noted in the original document from 2003, adherence to the recommendations will improve the precision of communications in this field, leading to more accurate comparison of technologies and results, and ultimately to improved patient outcomes. Online supplemental material is available for this article .


Journal of The American College of Surgeons | 2012

Ablation of Perivascular Hepatic Malignant Tumors with Irreversible Electroporation

T. Peter Kingham; Ami M. Karkar; Michael I. D'Angelica; Peter J. Allen; Ronald P. DeMatteo; George I. Getrajdman; Constantinos T. Sofocleous; Stephen B. Solomon; William R. Jarnagin; Yuman Fong

BACKGROUND Ablation is increasingly used to treat primary and secondary liver cancer. Ablation near portal pedicles and hepatic veins is challenging. Irreversible electroporation (IRE) is a new ablation technique that does not rely on heat and, in animals, appears to be safe and effective when applied near hepatic veins and portal pedicles. This study evaluated the safety and short-term outcomes of IRE to ablate perivascular malignant liver tumors. STUDY DESIGN A retrospective review of patients treated with IRE between January 1, 2011 and November 2, 2011 was performed. Patients were selected for IRE when resection or thermal ablation was not indicated due to tumor location. Treatment outcomes were classified by local, regional, and systemic recurrence and complications. Local failure was defined as abnormal enhancement at the periphery of an ablation defect on post-procedure contrast imaging. RESULTS Twenty-eight patients had 65 tumors treated. Twenty-two patients (79%) were treated via an open approach and 6 (21%) were treated percutaneously. Median tumor size was 1 cm (range 0.5 to 5 cm). Twenty-five tumors were <1 cm from a major hepatic vein; 16 were <1 cm from a major portal pedicle. Complications included 1 intraoperative arrhythmia and 1 postoperative portal vein thrombosis. Overall morbidity was 3%. There were no treatment-associated mortalities. At median follow-up of 6 months, there was 1 tumor with persistent disease (1.9%) and 3 tumors recurred locally (5.7%). CONCLUSIONS This early analysis of IRE treatment of perivascular malignant hepatic tumors demonstrates safety for treating liver malignancies. Larger studies and longer follow-up are necessary to determine long-term efficacy.


Journal of Vascular and Interventional Radiology | 2014

Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.

Muneeb Ahmed; Luigi Solbiati; Christopher L. Brace; David J. Breen; Matthew R. Callstrom; J. William Charboneau; Min Hua Chen; Byung Ihn Choi; Thierry de Baere; Gerald D. Dodd; Damian E. Dupuy; Debra A. Gervais; David Gianfelice; Alice R. Gillams; Fred T. Lee; Edward Leen; Riccardo Lencioni; Peter Littrup; Tito Livraghi; David Lu; John P. McGahan; Maria Franca Meloni; Boris Nikolic; Philippe L. Pereira; Ping Liang; Hyunchul Rhim; Steven C. Rose; Riad Salem; Constantinos T. Sofocleous; Stephen B. Solomon

Image-guided tumor ablation has become a well-established hallmark of local cancer therapy. The breadth of options available in this growing field increases the need for standardization of terminology and reporting criteria to facilitate effective communication of ideas and appropriate comparison among treatments that use different technologies, such as chemical (eg, ethanol or acetic acid) ablation, thermal therapies (eg, radiofrequency, laser, microwave, focused ultrasound, and cryoablation) and newer ablative modalities such as irreversible electroporation. This updated consensus document provides a framework that will facilitate the clearest communication among investigators regarding ablative technologies. An appropriate vehicle is proposed for reporting the various aspects of image-guided ablation therapy including classification of therapies, procedure terms, descriptors of imaging guidance, and terminology for imaging and pathologic findings. Methods are addressed for standardizing reporting of technique, follow-up, complications, and clinical results. As noted in the original document from 2003, adherence to the recommendations will improve the precision of communications in this field, leading to more accurate comparison of technologies and results, and ultimately to improved patient outcomes.


Annals of Surgery | 2008

Combined Portal Vein Embolization and Neoadjuvant Chemotherapy As a Treatment Strategy for Resectable Hepatic Colorectal Metastases

Anne M. Covey; Karen T. Brown; William R. Jarnagin; Lynn A. Brody; Lawrence H. Schwartz; Scott Tuorto; Constantinos T. Sofocleous; Michael I. D'Angelica; George I. Getrajdman; Ronald P. DeMatteo; Nancy E. Kemeny; Yuman Fong

Objectives:The objectives of this study are 1) to determine whether the future liver remnant will grow after portal vein embolization (PVE) in patients with colon cancer on concurrent chemotherapy and 2) to determine whether recovery after extended hepatectomy is improved after PVE. Purpose:Neoadjuvant chemotherapy followed by hepatic resection is an increasingly used therapeutic strategy for curative treatment for colorectal metastases. However, such chemotherapy may result in steatosis, liver damage, and compromised liver regeneration and recovery. This study aims to determine whether PVE can be used during neoadjuvant therapy to enhance growth of future residual liver and to improve postoperative recovery. Methods:From September 1999 to September 2004, 100 patients with colorectal metastases to the liver were subjected to PVE as preparation for extended hepatic resection, 43 of whom were embolized during neoadjuvant chemotherapy. Liver growth was examined by computed tomography volumetric analysis. Clinical outcomes of the 71 patients subsequently resected were compared with 100 consecutive patients subjected to extended resection without PVE (controls). Results:After a median wait of 30 ± 2 days after PVE, patients on neoadjuvant chemotherapy experienced a median contralateral (nonembolized) liver growth of 22% ± 3% compared with 26% ± 3% for those without chemotherapy (P = NS). The number of patients with <5% growth was also similar: 4 of 43 versus 6 of 57 (P = NS). Comparison of patients resected after PVE to a simultaneous cohort of 100 consecutive patients subjected to extended resection without prior PVE demonstrated a lower fresh frozen plasma requirement (P = 0.01), a lower peak bilirubin (P = 0.002), and a shorter length of stay (P = 0.03). Mortality was similar (0% vs. 2%). Conclusions:Liver growth occurs after PVE even when cytotoxic chemotherapy is administered. No major complications occurred with PVE. Patients requiring major hepatic resection should be considered for PVE during neoadjuvant chemotherapy to improve subsequent recovery after resection.


Journal of Vascular and Interventional Radiology | 2008

Transcatheter Arterial Embolization with Only Particles for the Treatment of Unresectable Hepatocellular Carcinoma

Mary A. Maluccio; Anne M. Covey; Leah Ben Porat; Joanna Schubert; Lynn A. Brody; Constantinos T. Sofocleous; George I. Getrajdman; William R. Jarnagin; Ronald P. DeMatteo; Leslie H. Blumgart; Yuman Fong; Karen T. Brown

PURPOSE To determine the survival of patients with hepatocellular carcinoma (HCC) treated with a standardized method of transcatheter arterial embolization (TAE) with small embolic particles intended to impart terminal vessel blockade, and to evaluate prognostic factors that impact overall survival. MATERIALS AND METHODS A total of 322 patients with HCC who underwent 766 embolizations from January 1997 to December 2004 were retrospectively reviewed. Selective embolization of vessels feeding individual tumors was performed with small (50 microm) polyvinyl alcohol or spherical embolic particles (40-120 microm) intended to cause terminal vessel blockade. Repeat embolization was performed in cases of evidence of persistent viable tumor or development of new lesions. Patient, tumor, and treatment characteristics were prospectively recorded and tested for prognostic significance by univariate and multivariate analysis. RESULTS The median survival time was 21 months, with 1-, 2-, and 3-year overall survival rates of 66%, 46%, and 33%, respectively. In patients without extrahepatic disease or portal vein involvement by tumor, the overall 1-, 2-, and 3-year survival rates increased to 84%, 66%, and 51%, respectively. Okuda stage, extrahepatic disease, diffuse disease (> or =5 tumors), and tumor size were independent predictors of survival on multivariate analysis. There were 90 complications (11.9%) in 75 patients, including eight deaths (2.5%), within 30 days of embolization. CONCLUSIONS Hepatic arterial embolization with small particles to cause terminal vessel blockade is an effective treatment method for patients with unresectable HCC. These data support our hypothesis that particles alone may be the critical component of catheter-directed embolotherapy.


American Journal of Roentgenology | 2011

Irreversible Electroporation Near the Heart: Ventricular Arrhythmias Can Be Prevented With ECG Synchronization

Ajita Deodhar; Timm Dickfeld; Gordon W. Single; William C. Hamilton; Raymond H. Thornton; Constantinos T. Sofocleous; Majid Maybody; Mithat Gonen; Boris Rubinsky; Stephen B. Solomon

OBJECTIVE Irreversible electroporation is a nonthermal ablative tool that uses direct electrical pulses to create irreversible membrane pores and cell death. The ablation zone is surrounded by a zone of reversibly increased permeability; either zone can cause cardiac arrhythmias. Our purpose was to establish a safety profile for the use of irreversible electroporation close to the heart. MATERIALS AND METHODS The effect of unsynchronized and synchronized (with the R wave on ECG) irreversible electroporation in swine lung and myocardium was studied in 11 pigs. Twelve lead ECG recordings were analyzed by an electrophysiologist for the presence of arrhythmia. Ventricular arrhythmias were categorized as major events. Minor events included all other dysrhythmias or ECG changes. Cardiac and lung tissue was submitted for histopathologic analysis. Electrical field modeling was performed to predict the distance from the applicators over which cells show electroporation-induced increased permeability. RESULTS At less than or equal to 1.7 cm from the heart, fatal (major) events occurred with all unsynchronized irreversible electroporation. No major and three minor events were seen with synchronized irreversible electroporation. At more than 1.7 cm from the heart, two minor events occurred with only unsynchronized irreversible electroporation. Electrical field modeling correlates well with the clinical results, revealing increased cell membrane permeability up to 1.7 cm away from the applicators. Complete lung ablation without intervening live cells was seen. No myocardial injury was seen. CONCLUSION Unsynchronized irreversible electroporation close to the heart can cause fatal ventricular arrhythmias. Synchronizing irreversible electroporation pulse delivery with absolute refractory period avoids significant cardiac arrhythmias.


Journal of The National Comprehensive Cancer Network | 2017

Colon cancer, version 1.2017: Clinical practice guidelines in oncology

Al B. Benson; Alan P. Venook; Lynette Cederquist; Emily Chan; Yi Jen Chen; Harry S. Cooper; Dustin A. Deming; Paul F. Engstrom; Peter C. Enzinger; Alessandro Fichera; Jean L. Grem; Axel Grothey; Howard S. Hochster; Sarah E. Hoffe; Steven R. Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha S. Krishnamurthi; Wells A. Messersmith; Mary F. Mulcahy; James D. Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M. Skibber; Constantinos T. Sofocleous; Elena M. Stoffel; Eden Stotsky-Himelfarb; Christopher G. Willett

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.


Journal of Clinical Oncology | 2016

Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone

Karen T. Brown; Richard K. G. Do; Mithat Gonen; Anne M. Covey; George I. Getrajdman; Constantinos T. Sofocleous; William R. Jarnagin; Michael I. D’Angelica; Peter J. Allen; Joseph P. Erinjeri; Lynn A. Brody; Gerald P. O’Neill; Kristian Johnson; Alessandra R. Garcia; Christopher Beattie; Binsheng Zhao; Stephen B. Solomon; Lawrence H. Schwartz; Ronald P. DeMatteo; Ghassan K. Abou-Alfa

PURPOSE Transarterial chemoembolization is accepted therapy for hepatocellular carcinoma (HCC). No randomized trial has demonstrated superiority of chemoembolization compared with embolization, and the role of chemotherapy remains unclear. This randomized trial compares the outcome of embolization using microspheres alone with chemoembolization using doxorubicin-eluting microspheres. MATERIALS AND METHODS At a single tertiary referral center, patients with HCC were randomly assigned to embolization with microspheres alone (Bead Block [BB]) or loaded with doxorubicin 150 mg (LC Bead [LCB]). Random assignment was stratified by number of embolizations to complete treatment, and assignments were generated by permuted blocks in the institutional database. The primary end point was response according to RECIST 1.0 (Response Evaluation Criteria in Solid Tumors) using multiphase computed tomography 2 to 3 weeks post-treatment and then at quarterly intervals, with the reviewer blinded to treatment allocation. Secondary objectives included safety and tolerability, time to progression, progression-free survival, and overall survival. This trial is currently closed to accrual. RESULTS Between December 2007 and April 2012, 101 patients were randomly assigned: 51 to BB and 50 to LCB. Demographics were comparable: median age, 67 years; 77% male; and 22% Barcelona Clinic Liver Cancer stage A and 78% stage B or C. Adverse events occurred with similar frequency in both groups: BB, 19 of 51 patients (38%); LCB, 20 of 50 patients (40%; P = .48), with no difference in RECIST response: BB, 5.9% versus LCB, 6.0% (difference, -0.1%; 95% CI, -9% to 9%). Median PFS was 6.2 versus 2.8 months (hazard ratio, 1.36; 95% CI, 0.91 to 2.05; P = .11), and overall survival, 19.6 versus 20.8 months (hazard ratio, 1.11; 95% CI, 0.71 to 1.76; P = .64) for BB and LCB, respectively. CONCLUSION There was no apparent difference between the treatment arms. These results challenge the use of doxorubicin-eluting beads for chemoembolization of HCC.


Journal of Vascular and Interventional Radiology | 2014

Percutaneous Ablation of Peribiliary Tumors with Irreversible Electroporation

Mikhail Silk; Thomas Wimmer; Kyungmouk Steve Lee; Govindarajan Srimathveeravalli; Karren T. Brown; Peter Kingham; Yuman Fong; Jeremy C. Durack; Constantinos T. Sofocleous; Stephen B. Solomon

PURPOSE To assess biliary complications after irreversible electroporation (IRE) ablation of hepatic tumors located < 1 cm from major bile ducts. MATERIALS AND METHODS A retrospective review was conducted of all percutaneous IRE ablations of hepatic tumors within 1 cm of the common, left, or right hepatic ducts at a single institution from January 2011 to September 2012. Computed tomography imaging performed before and after treatment was examined for evidence of bile duct dilatation, stricture, or leakage. Serum bilirubin and alkaline phosphatase levels were analyzed for evidence of biliary injury. RESULTS There were 22 hepatic metastases in 11 patients with at least one tumor within 1 cm of the common, left, or right hepatic duct that were treated with IRE ablations in 15 sessions. Median tumor size treated was 3.0 cm (mean, 2.8 cm ± 1.2, range, 1.0-4.7 cm). Laboratory values obtained after IRE were considered abnormal after four treatment sessions in three patients (bilirubin, 2.6-17.6 mg/dL; alkaline phosphatase, 130-1,035 U/L); these abnormal values were transient in two sessions. Two patients had prolonged elevation of values, and one required stent placement; both of these conditions appeared to be secondary to tumor progression rather than bile duct injury. CONCLUSIONS This clinical experience suggests that IRE may be a treatment option for centrally located liver tumors with margins adjacent to major bile ducts where thermal ablation techniques are contraindicated. Further studies with extended follow-up periods are necessary to establish the safety profile of IRE in this setting.

Collaboration


Dive into the Constantinos T. Sofocleous's collaboration.

Top Co-Authors

Avatar

Stephen B. Solomon

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Karen T. Brown

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Anne M. Covey

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Joseph P. Erinjeri

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Lynn A. Brody

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

George I. Getrajdman

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Elena N. Petre

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Raymond H. Thornton

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Mithat Gonen

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

William Alago

Memorial Sloan Kettering Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge